sofosbuvir and daclatasvir - versus control - for COVID 19 hospitalized pdf   xlsx method abbreviations

Outcome Relative effect 95%CI LoD Trt. better when I2 k (RCT/OBS) Bayesian probability Overall ROB Publication bias Degree of certainty Endpoint importance Published MA

efficacy endpoints 00

death D28 1.10 [0.77, 1.57]< 10%1 study (1/-)29.8 %some concernnot evaluable moderatecrucial-
deaths 0.97 [0.58, 1.63]< 112%3 studies (3/-)54.4 %some concernnot evaluable moderatecrucial-
clinical improvement (14-day) 3.63 [1.02, 12.93]> 10%1 study (1/-)97.6 %some concernnot evaluable moderateimportant-
mechanical ventilation 0.73 [0.25, 2.10]< 153%3 studies (3/-)72.0 %some concernnot evaluable moderateimportant-
ICU admission 0.38 [0.07, 2.08]< 10%1 study (1/-)86.7 %some concernnot evaluable moderatenon important-
recovery 1.18 [0.73, 1.90]> 176%2 studies (2/-)75.0 %some concernnot evaluable moderatenon important-

safety endpoints 00

serious adverse events 1.01 [0.06, 16.47]< 10%2 studies (2/-)49.7 %some concernnot evaluable moderateimportant-

LoD: level of statistical demonstration: Statistically conclusive: statistically significant with a strict control of overall risk of type 1 error (statistically demonstrated), does not take into account the risk of bias; suggested: nominally statistically significant but without a strict control of overall risk of type 1 error; inconclusive: not nominally statistically significant; safety concerns;
Bayesian probability: Bayesian posterior probability of treatment effect (computed with a noninformative prior); ROB: risk of bias; k: number of studies; published MA: number of published meta-analysis on the same topic; degree of certainty adapted from GRADE. Trt. better when: indicates when the relative treatment effect shows that the studied treatment is better than control.